Short description
Virax Biolabs is a biotechnology company focusing on the prevention, detection, and diagnosis of viral diseases.
Description
Virax Biolabs is a biotechnology company focusing on the prevention, detection, and diagnosis of viral diseases. Virax is a revenue-generating group established in 2013 whose primary business is the proprietary development and global distribution of in vitro diagnostic (IVD) test kits.
Virax Biolabs is developing an immunology platform based on T-Cell testing. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria & Human Papilloma Virus.
Virax Biolabs’ vision is to facilitate the transition into the 'new normal’ during and post-pandemic through the provision of the latest medical equipment and technology.
Virax Biolabs is acquiring innovative biosensor technology from which it intends to develop into novel point-of-care biomarker testing devices, that rival lab-based ELISA tests for accuracy.
Last funding
No Way
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
London, England, United Kingdom, Europe
Founded on
March 11, 2013
Exited on
July 21, 2022
Went public on
July 21, 2022
Stock symbol
VRAX
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Founders
Cameron Shaw, Greg Aldridge, James Foster, Mark Ternouth, Tomasz George